How Reflux Medications Affect the Microbiome of Infants

GERD Clinical Trial

Official title:

Effect of Histamine-2 Receptor Antagonists on the Microbiome of Full Term Infants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03747991
• Other study ID #: 1231469
• Status: Completed
• Start date: August 13, 2018
• Est. completion date: July 31, 2019

Study information

• Verified date: June 2024
• Source: Nemours Children's Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The changes in the organisms making up the gut microbiota in infants who are taking anti-acid reflux medications (histamine 2 receptor antagonists) as compared to infants who are not taking these medications is not well-studied or understood. Whether these medications change the gut microbiota and microbiome, and what that change may imply for children on these medications, is the focus of this study.

Description:

Gut microbiota dysbiosis is associated with diseases ranging from localized gastrointestinal disorders to neurologic, respiratory, metabolic, hepatic, and cardiovascular illnesses. The microbial colonization of the infant gut is known to play a key role in immunologic and metabolic pathways impacting on human health. Disruptions during the complex process of microbial colonization have been shown to increase disease susceptibility during life. A variety of factors are known to influence the gut microbiota, including mode of delivery of neonate, host genetic factors, hose immune response, diet, xenobiotics and other drugs, infections, and environmental microbial exposures.

The diagnosis of gastroesophageal reflux disease in the infant population has increased during the past two decades. Acid suppression medications are used commonly in infants for gastroesophageal reflux disease and other acid-related conditions despite little evidence of their efficacy. Multiple studies have shown adverse effects in pediatric patients using either proton pump inhibitors or H2 receptor antagonists, the two classes of acid suppression medications that are most frequently used in children. Some of these adverse effects may result from alterations in the microbiome caused by these medications. Prior studies have demonstrated significant changes in microbial composition of both gastric and intestinal microbiota with proton pump inhibitor use (5), but to the investigators' knowledge, no prior studies have looked at the effect of H2 receptor antagonists on the microbiome in healthy, full term infants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: July 31, 2019
• Est. primary completion date: April 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Months to 12 Months

Eligibility

Inclusion Criteria:

• Full term, at least 2 months of age

• No exposure OR at least 14 days of exposure to H2-receptor antagonist medication

• No exposure to probiotics or antibiotics

Exclusion Criteria:

• Current or recent (within the past 14 days) gastrointestinal infection (viral, bacterial, or fungal)

• Gastrointestinal mucosal disease, or have clinically significant constipation

• Any history of exposure to proton pump inhibitors

• Unvaccinated infants

• Infants with weight-for-length either below the 3rd percentile for age or above the 97th percentile for age

• Infants with rapid weight gain, defined as change in weight-for-length z-score exceeding +0.67 from birth to 4 months of age or birth to 6 months of age

Related Conditions & MeSH terms

• Dysbiosis
• GERD

Locations

Country	Name	City	State
United States	Alfred I. duPont Hospital for Children	Wilmington	Delaware

Sponsors (1)

Lead Sponsor	Collaborator
Nemours Children's Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Microbiome taxa	16S Metagenomic taxonomy of gut microbiome	At time of sampling - once at enrollment